Literature DB >> 29527667

Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.

Jorge J Castillo1, Thomas Guerrero-Garcia2, Francesco Baldini3, Emmanuelle Tchernonog4, Guillaume Cartron4, Slavisa Ninkovic5, Kate Cwynarski5, Daan Dierickx6, Thomas Tousseyn6, Frederick Lansigan7, Yevgeny Linnik7, Renzo Mogollon8, Jose-Tomás Navarro9, Adam J Olszewski10, John L Reagan10, Pasquale Fedele11, Michael Gilbertson11, George Grigoriadis11, Michele Bibas3.   

Abstract

Entities:  

Keywords:  bortezomib; chemotherapy; plasmablastic lymphoma; survival

Mesh：

Substances：

Year:  2018        PMID： 29527667     DOI： 10.1111/bjh.15156

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  14 in total

1.  Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas.

Authors:  Erin G Reid; David Looney; Frank Maldarelli; Ariela Noy; David Henry; David Aboulafia; Juan Carlos Ramos; Joseph Sparano; Richard F Ambinder; Jeannette Lee; Ethel Cesarman; Sara Yahyaei; Ronald Mitsuyasu; William Wachsman
Journal:  Blood Adv       Date:  2018-12-26

Review 2.  Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review.

Authors:  Hirotaka Mori; Masahiko Fukatsu; Hiroshi Ohkawara; Yuka Oka; Yuki Kataoka; Shunsuke Taito; Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2021-08-30       Impact factor: 2.490

3.  Clinical Features of Plasmablastic Lymphoma: Case Series From an Asian Tertiary Cancer Center and Literature Review.

Authors:  Daniel Ren Yi Yap; Grace Fangmin Tan; Esther Wei Yin Chang; Valerie Shiwen Yang; Eileen Yi Ling Poon; Nagavalli Somasundaram; Mohamad Farid; Tiffany Tang; Miriam Tao; Soon Thye Lim; Jason Yongsheng Chan
Journal:  J Hematol       Date:  2020-08-14

4.  An unusual case of plasmablastic lymphoma presenting as dermatomyositis.

Authors:  Ashlyn Rui Yin Chee; Teng Fong Ng; Stephanie Jin Ping Lam; Matthew Wright; Michael F Leahy
Journal:  Clin Case Rep       Date:  2020-03-10

5.  Clinicopathological characteristics and MYC status determine treatment outcome in plasmablastic lymphoma: a multi-center study of 76 consecutive patients.

Authors:  Hanno M Witte; Nadine Hertel; Hartmut Merz; Heinz-Wolfram Bernd; Veronica Bernard; Stephanie Stölting; Nikolas von Bubnoff; Alfred C Feller; Niklas Gebauer
Journal:  Blood Cancer J       Date:  2020-05-29       Impact factor: 11.037

6.  Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.

Authors:  Hanno M Witte; Axel Künstner; Nadine Hertel; Heinz-Wolfram Bernd; Veronica Bernard; Stephanie Stölting; Hartmut Merz; Nikolas von Bubnoff; Hauke Busch; Alfred C Feller; Niklas Gebauer
Journal:  Blood Adv       Date:  2022-01-25

7.  Case Report: First Occurrence of Plasmablastic Lymphoma in Activated Phosphoinositide 3-Kinase δ Syndrome.

Authors:  Zexi Yin; Xin Tian; Runying Zou; Xiangling He; Keke Chen; Chengguang Zhu
Journal:  Front Immunol       Date:  2021-12-21       Impact factor: 7.561

8.  Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma.

Authors:  Jiao Cai; Ling Qiu; Lei Ma; Nan Zhang; Fang-Yi Fan
Journal:  Front Med (Lausanne)       Date:  2021-12-03

Review 9.  HIV-Associated Lymphomas: Progress and New Challenges.

Authors:  Georgios N Pongas; Juan C Ramos
Journal:  J Clin Med       Date:  2022-03-07       Impact factor: 4.241

10.  Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide.

Authors:  Lili Cheng; Qi Song; Mengke Liu; Yan Wang; Hongmei Yi; Ying Qian; Pengpeng Xu; Shu Cheng; Chaofu Wang; Li Wang; Weili Zhao
Journal:  Front Immunol       Date:  2021-07-12       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.